Palasma Exchange in Autoimmune Neurological Diseases

<p>This systematic review and meta-analysis evaluates the <strong>effectiveness and safety</strong> of <strong>therapeutic plasma exchange (TPE)</strong> for treating <strong>autoimmune neurological diseases (ANDs)</strong>. By analyzing 38 studies involving 2,199 patients, the research indicates that TPE leads to a <strong>high rate of clinical improvement</strong> across various conditions, including <strong>Guillain-Barré syndrome</strong> and <strong>myasthenia gravis</strong>. While age appears to influence the success rate—with <strong>younger patients showing better responses</strong> than those over 60—geographic region and specific disease types do not show statistically significant differences in efficacy. The study finds an all-cause hospital <strong>mortality rate of 4%</strong>, though these deaths are largely attributed to the <strong>progression of the underlying disease</strong> rather than the procedure itself. Common but manageable <strong>adverse events</strong> identified include <strong>hypotension, coagulation disorders, and infections</strong>. Ultimately, the authors conclude that TPE is a <strong>safe and beneficial intervention</strong>, though they call for more rigorous, multicenter trials to refine treatment protocols.</p>